The mutational profile consisted of single nucleotide variants in ARID1A (premature stop codon), ERBB2 (TCGA hotspot), ERBB3, and TERT (TCGA hotspot), and a multi-base deletion causing a frameshift in ZFP36L1. The following prognostic insight was summarized from available literature: ARID1A mutation has been associated with BCG-resistance (9), ERBB2 and ERBB3 mutations are more prevalent in non-papillary/CIS tumors (consistent with negative ureteroscopy) (10), and the presence of insertion-deletions are also enriched in high-grade tumors (8). The gene discussed is ERBB2; the disease is in situ carcinoma.